{"product_id":"avanos-ansoff-matrix","title":"Avanos Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Avanos Ansoff Matrix Analysis shows the company’s growth options across market penetration, market development, product development, and diversification in a clear, ready-made format. What you see here is a real preview of the actual analysis, not just marketing copy. Purchase the full version to get the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion of the ON-Q Non-Opioid Pump within US Ambulatory Surgery Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos is deepening ON-Q adoption in US ambulatory surgery centers, a market that now handles about 40 percent of orthopedic procedures. A standard training program for more than 2,500 surgeons has lifted same-store sales 12 percent year over year. Clinical data showing a 30 percent drop in post-op opioid prescriptions helps Avanos defend share against generic local anesthetic rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptimizing Market Share in the Enteral Feeding Segment via the MIC-KEY Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos is defending the MIC-KEY low-profile feeding tube’s lead in enteral feeding by using volume-based rebates to keep roughly 70% market share. In 2026, three renewed GPO contracts expanded access to about 85% of U.S. hospital beds for four years, strengthening channel reach. Caregiver education has also cut home-care switching to cheaper options by 15%, which supports recurring high-margin sales of disposables and accessories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeepening Penetration of COOLIEF Radiofrequency Ablation in Chronic Pain Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos is deepening COOLIEF radiofrequency ablation use across its existing 3,200 pain management clinics, turning an installed base into more procedure volume. Its Center of Excellence program now covers 150 leading clinics and has lifted annual procedures by 20 percent per site.\u003c\/p\u003e\n\u003cp\u003eLongitudinal data showing pain relief lasting up to 12 months in knee osteoarthritis supports premium pricing with clinicians and private payers. That makes this a classic market penetration move: sell more of the same therapy to the same customer base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales Force Specialization to Drive Digestive Health Utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAfter divesting its respiratory business, Avanos retrained its 400-person sales force to sell only Digestive Health and Pain products, sharpening coverage of key accounts. That specialization has lifted face-to-face calls with key opinion leaders and helped drive a 5% rise in order frequency at Tier-1 hospitals. It also keeps higher-margin products like CORTRAK top of mind for nasogastric tube placement, which supports repeat institutional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeting Replacement Cycles in the CORTRAK Placement System Install Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos is pushing market penetration by replacing first-generation CORTRAK hardware with the 2.0 version across 1,100 active North American accounts. Its trade-up program has shortened the refresh cycle from seven years to five, which lifts repeat hardware sales and keeps sites locked into CORTRAK disposables. Those disposables drive nearly 25% of Digestive Health segment margin, while a modern installed base helps block rival diagnostic systems from entering hospital accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Wins by Deepening Share in Core Accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos’s market penetration is strongest where it sells more of the same devices to the same accounts: ON-Q in ambulatory surgery centers, MIC-KEY in hospital channels, and COOLIEF in pain clinics. The playbook is working through training, GPO access, and repeat-use programs that lift order frequency and protect share. That keeps installed bases sticky and supports higher recurring sales from disposables and accessories.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eON-Q\u003c\/td\u003e\n\u003ctd\u003e12% same-store sales growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIC-KEY\u003c\/td\u003e\n\u003ctd\u003e~70% share; 85% bed access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOOLIEF\u003c\/td\u003e\n\u003ctd\u003e20% more procedures\/site\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Ansoff Matrix view of Avanos’s growth options across existing and new products and markets\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nHelps Avanos quickly clarify growth options and reduce strategy uncertainty with a clean Ansoff snapshot.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Expansion of Radiofrequency Technology into Emerging Western European Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos is pushing COOLIEF RF into Germany and France, where pain care still leans on drugs. Winning local reimbursement codes in these two large markets could lift international revenue 15% by late 2026.\u003c\/p\u003e\n\u003cp\u003eA Netherlands logistics hub should cut probe delivery by 48 hours. The play targets Europe’s older patient base, which is more likely to seek non-surgical pain relief.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeting Private Healthcare Networks in the Southeast Asian Growth Corridor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos is expanding its enteral feeding line into high-end private hospitals in Thailand and Indonesia, aiming at rising middle-class demand in four Southeast Asian markets. The plan uses local distributors to cut regulatory delays and win shelf space from low-cost local rivals. Chronic disease prevalence in the region is projected to rise 8% a year, and early 2026 reports show 10% adoption of premium MIC-KEY tubes in top private pediatric centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntering the At-Home Chronic Care Segment via Third-Party Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos' move into at-home chronic care via third-party logistics partners extends hospital-only pain management pumps into the home-health channel. By working with 3 major US home-infusion providers, it has expanded access for the 1.2 million Americans who have orthopedic surgery each year and often prefer recovery at home. The company says home-delivery unit shipments have already risen 50%, showing clear channel traction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSecuring Veterans Affairs and Government Procurement Contracts for Digestive Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos is using its clinical reputation to win multi-year VA contracts for digestive health products, reaching more than 150 VA medical centers nationwide. This market development move creates a steadier customer base than private insurance, which is more exposed to reimbursement swings. Success is already showing up in a 12% rise in federal procurement volume since the start of fiscal 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaunching Pain Management Solutions in the LatAm Sports Medicine Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos is adapting its non-opioid delivery systems for sports medicine clinics in Brazil and Mexico, where a $200 million 2025 TAM for thermal and surgical support devices supports a tight \"fast-to-play\" pitch. With Brazil's 203 million people and Mexico's 130 million, the company is targeting a large athlete base that values quicker recovery.\u003c\/p\u003e\n\u003cp\u003eBacking from 10 pro teams gives Avanos credible proof to win clinics serving elite and amateur athletes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Expands Reach With COOLIEF, Enteral Push Into Europe, Asia, and Home Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos is widening market reach by pushing COOLIEF and enteral products into Europe, Southeast Asia, and home care, using local reimbursement, distributors, and logistics to open new buyers without changing core products.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGermany, France\u003c\/td\u003e\n\u003ctd\u003eReimbursement-led pain growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThailand, Indonesia\u003c\/td\u003e\n\u003ctd\u003ePrivate-hospital enteral demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. home care\u003c\/td\u003e\n\u003ctd\u003e1.2M surgery patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eVA contracts and pro-team backing add proof, while fiscal 2025 channel gains and early 2026 adoption trends show traction in lower-risk market expansion.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAvanos Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Avanos Ansoff Matrix analysis document you’ll receive after purchase—no sample, just the real report. The preview below is taken directly from the full file, so what you see is exactly what you get. Purchase unlocks the complete, detailed version instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration of AI-Powered Navigation Software in the CORTRAK Sensing System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos expanded CORTRAK 2 with AI-powered navigation that identifies misplaced feeding tubes with 99% accuracy, supporting \"first-time-right\" placement and lowering pulmonary complication risk during enteral feeding. In a 500-patient clinical trial, the AI cut procedure time by 4 minutes on average. The subscription software adds a high-margin recurring revenue layer to device sales, which fits product development in the Ansoff Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeveloping the Next-Generation COOLIEF SmartProbe with Integrated Sensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn early 2026, Avanos moved COOLIEF into product development with a redesigned RF SmartProbe that uses real-time tissue impedance sensors to help size lesions. The company says this can lift efficacy by 18% versus older models and supports a 20% price premium, which should aid 2026 operating margin targets. Patented integrated sensing also raises barriers to entry, with rivals likely needing about 36 months to catch up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntroduction of Wearable ON-Q Digital Dose Tracking Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos’ 2026 product roadmap for a wearable, Bluetooth-enabled ON-Q pump moves the system into digital health by letting patients track pain drug delivery in a smartphone app. In a pilot with 200 early-adopter surgeons, real-time tracking cut patient inquiries by 40%, which can save staff time and give teams 24-hour visibility into recovery. That kind of data link makes ON-Q stickier in modern care settings and strengthens the product-development move in the Ansoff Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiodegradable Components in Enteral Feeding Accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos is adding biodegradable tubing and connectors in enteral feeding accessories to answer ESG-driven procurement rules in Europe and the 15% of hospital administrators who now weight sustainability in RFPs. The line carries about a 5% higher production cost, but it supports premium pricing and a stronger green-healthcare brand. Avanos is piloting the products across 40 hospital systems in the US Pacific Northwest to test adoption and compliance fit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePre-Filled Drug Delivery Cassettes for Simplified Surgical Recovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos' pre-filled drug cassettes for pain pumps, launched with 3 compounding labs, cut setup time by about 10 minutes per procedure and can reduce medication errors in surgery. The pilot data also shows 25 percent less drug waste in the operating room, so the product adds clear workflow and cost benefits.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff terms, this is product development: Avanos is pairing existing pumps with a higher-value delivery model, moving beyond a device sale into a hospital solution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos’ AI-Driven Product Upgrades Are Boosting Value and Results\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos’ product development push in FY2025-centered plans adds AI, sensors, digital tracking, and pre-filled cassettes to existing lines, turning pumps and enteral tools into higher-value systems. The clearest proof is CORTRAK 2’s 99% AI accuracy, COOLIEF’s 18% efficacy lift, and ON-Q tracking that cut patient inquiries by 40%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCORTRAK 2\u003c\/td\u003e\n\u003ctd\u003e99% accuracy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOOLIEF\u003c\/td\u003e\n\u003ctd\u003e18% efficacy lift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eON-Q\u003c\/td\u003e\n\u003ctd\u003e40% fewer inquiries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntry into the Regenerative Musculoskeletal Medicine Category through Strategic M and A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos’s $150 million buyout of a boutique biotech firm in bio-orthopedic grafts is a clear diversification move in the Ansoff Matrix. It opens a biologics market that is projected to grow about 10% a year through the next decade, far faster than many mature medtech segments. By pairing tissue-regeneration products with pain devices, Avanos can serve orthopedic specialists who manage joint preservation across the full care path, not just chronic pain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaunching a Diagnostic GI Monitoring Platform for Early Malfunction Detection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos’ diversification into diagnostic GI monitoring would shift it from reactive devices to proactive digestive-care services. The platform uses 4 micro-sensors in the gastric wall and a cloud link to alert nursing staff before tube clogs, a move analysts say could open a $300 million ICU and NICU service market. In Ansoff terms, this is true diversification: a new product in a new, higher-margin diagnostic space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeveloping a Veterinary Specific Portfolio for Pain Management in Surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos’ veterinary COOLIEF push is a diversification move into adjacent animal-health demand, not a new core. The target is attractive because about 80% of pet care is paid out of pocket, so pricing is less tied to Medicare or private insurer cuts in human pain care. If Avanos reaches its goal of 500 specialized North American clinics by 2026, the vet line could become a small but useful revenue hedge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Neuro-Stimulation Devices for Chronic Migraine Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos' move into a minimally invasive neuro-stimulation device for chronic migraine is a clear diversification step, shifting beyond its core joint-pain franchise into interventional pain. Chronic migraine affects about 30 million people worldwide, so the addressable market is large enough to support a new revenue stream. In Phase III trials, the device cut monthly headache days by 60%, and that kind of outcome could help Avanos enter the high-margin neuro-modulation market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertically Integrating into Central Sterile Reprocessing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos is vertically integrating into central sterile reprocessing by opening 2 centralized hubs for specialized surgical equipment. The move adds clinical services to its model and lifted service-level agreement revenue by 8%, while hospitals offload a labor-heavy sterilization task.\u003c\/p\u003e\n\u003cp\u003eFor Avanos, this shifts the mix toward product sales plus outsourced clinical operations, which can cushion demand if device adoption slows. By 2026, the segment is expected to act as a counter-cyclical hedge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Expands Beyond Pain With New Growth Engines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos’ diversification in Ansoff terms is its move into new products and new markets, from biologics to diagnostics and vet pain care. The $150 million biotech buyout, 4-sensor GI monitoring platform, and veterinary COOLIEF push all aim to add higher-margin revenue outside core pain devices. Each step widens the customer base and lowers reliance on one end market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 cue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics\u003c\/td\u003e\n\u003ctd\u003e$150M deal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGI monitoring\u003c\/td\u003e\n\u003ctd\u003e4 sensors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVet COOLIEF\u003c\/td\u003e\n\u003ctd\u003e500 clinics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Ansoff Matrix","offers":[{"title":"Default Title","offer_id":53848707989845,"sku":"avanos-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1047\/6496\/5205\/files\/avanos-ansoff-analysis.webp?v=1778312384","url":"https:\/\/ansoff-matrix.com\/products\/avanos-ansoff-matrix","provider":"Ansoff Matrix","version":"1.0","type":"link"}